A new formulation of extended-release methylphenidate (PRC-063) was approved to treat ADHD. This meta-analysis was conducted to study the efficacy and safety of PRC-063 for ADHD.
Method:
We searched for published trials to October 2022 in several databases.
Results:
A total of 1,215 patients from 5 RCTs were included. We observed significant improvement for PRC-063 in ADHD Rating Scale (ADHD-RS; MD = −6.73, 95% CI [−10.34, −3.12]) compared with placebo. The effect of PRC-063 on the sleep problems due to ADHD was not statistically different from placebo. Six subscales of Pittsburg Sleep Quality Index (PSQI) showed no statistical significance between PRC-063 and placebo. The result showed no significant difference comparing PRC-063 with placebo in serious treatment-emergent adverse events (TEAEs) (RR = 0.80, 95% CI [0.03, 19.34]). In subgroup analysis according to age, PRC-063 was more efficacious in minors compare to adults.
Conclusion:
PRC-063 is an efficacious and safe treatment for ADHD, especially in children and adolescents.
BoesenK.Paludan-MüllerA. S.GøtzscheP. C.JørgensenK. J. (2022). Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews, 2, CD012857.
2.
BuysseD. J.ReynoldsCf3rdMonkT. HBermanS. RKupferD. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28, 193–213.
3.
CândidoR. C. F.MenezesdePaduaC. A.GolderS.JunqueiraD. R. (2021). Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews, 1, CD013011.
4.
ChildressA.CutlerA. J.MarraffinoA. H.BhaskarS.DonnellyG. (2022). Randomized, double-blind, placebo-controlled, parallel-group, adult laboratory classroom study of the efficacy and safety of PRC-063 (Extended-Release methylphenidate) for the treatment of ADHD. Journal of Attention Disorders, 26, 857–869.
5.
ChildressA. C.BramsM. N.CutlerA. J.DonnellyG. A. E.BhaskarS. (2020). Efficacy and safety of multilayer, extended-release methylphenidate (PRC-063) in children 6-12 years of age with attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology, 30, 580–589.
6.
ConnersC. K.ErhardtD.SparrowE. (2002). Conners' adult ADHD rating scales–Self-report: Short version (CAARS–S: S). Toronto: Multi-Health Systems Inc. https://documents.acer.org/caars-self-s-int_1.pdf
7.
CorteseS.AdamoN.Del GiovaneC.Mohr-JensenC.HayesA. J.CarucciS.AtkinsonL. Z.TessariL.BanaschewskiT.CoghillD.HollisC.SimonoffE.ZuddasA.BarbuiC.PurgatoM.SteinhausenH. C.ShokranehF.XiaJ.CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5, 727–738.
8.
CumpstonM.LiT.PageM. J.ChandlerJ.WelchV. A.HigginsJ. P.ThomasJ. (2019). Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of interventions. Cochrane Database of Systematic Reviews, 10, Ed000142.
9.
DalrympleR. A.McKenna MaxwellL.RussellS.DuthieJ. (2020). NICE guideline review: Attention deficit hyperactivity disorder: Diagnosis and management (NG87). Archives of Disease in Childhood-Education and Practice Edition, 105, 289–293.
10.
DonnellyG.RodriguezR.CataldoM.BhaskarS. (2021). 5.8 Comparison of Adhansia XR and concerta pharmacokinetic profiles. Journal of the American Academy of Child and Adolescent Psychiatry, 60, S152–S52.
11.
DuPaulG. J.PowerT. J.AnastopoulosA. D.ReidR. (2016). ADHD rating scale? 5 for children and adolescents: Checklists, norms, and clinical interpretation. Guilford Publications.
GouldK. L.PorterM.LynehamH. J.HudsonJ. L. (2018). Cognitive-behavioral therapy for children with anxiety and comorbid attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 57, 481–490.e2.
14.
Guy, W.; US Department of Health, Education and Welfare Publication 76. (1976). Clinical global impressions scale. ECDEU Assessment Manual for Psychopharmacology, 338, 221–227.
15.
KatzmanM. A.MattinglyG.KlassenL. J.CataldoM. J.DonnellyG. A. E. (2020). Randomized controlled crossover trials of the pharmacokinetics of PRC-063, a novel multilayer extended-release formulation of methylphenidate, in healthy adults. Journal of Clinical Psychopharmacology, 40, 579–587.
16.
KidwellK. M.Van DykT. R.LundahlA.NelsonT. D. (2015). Stimulant medications and sleep for youth with ADHD: A meta-analysis. Pediatrics, 136, 1144–1153.
17.
KimH. W.YoonI. Y.ChoS. C.KimB. N.ChungS.LeeH.KimC. W.ParkS. K.YooH. J. (2010). The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. International Clinical Psychopharmacology, 25, 107–115.
18.
OwensJ.WeissM.NordbrockE.MattinglyG.WigalS.GreenhillL. L.ChangW. W.ChildressA.KupperR. J.AdjeiA. (2016). Effect of aptensio XR (Methylphenidate HCl Extended-Release) capsules on sleep in children with attention-Deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 26, 873–881.
19.
PageM. J.McKenzieJ. E.BossuytP. M.BoutronI.HoffmannT. C.MulrowC. D.ShamseerL.TetzlaffJ. M.AklE. A.BrennanS. E.ChouR.GlanvilleJ.GrimshawJ. M.HróbjartssonA.LaluM. M.LiT.LoderE. W.Mayo-WilsonE.McDonaldS.. . . MoherD. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 74, 790–799.
20.
PolanczykG. V.WillcuttE. G.SalumG. A.KielingC.RohdeL. A. (2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43, 434–442.
21.
QuinnD. M.BodeT. D.DonnellyG.ReizJ. L. (2016). 6.49 pharmacokinetics of a novel, extended-release formulation of methylphenidate (PRC-063) in adolescents with attention-deficit/hyperactivity disorder and in healthy adults at steady state. Journal of the American Academy of Child Reiz, and Adolescent Psychiatry, 55, S219–S20.
22.
SchranteeA.TammingaH. G. H.BouzianeC.BottelierM. A.BronE. E.MutsaertsH. J. M. M.ZwindermanA. H.GrooteI. R.RomboutsS. A. R. B.LindauerR. J. L.KleinS.NiessenW. J.OpmeerB. C.BoerF.LucassenP. J.AndersenS. L.GeurtsH. M.RenemanL. (2016). Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/Hyperactivity Disorder: A randomized clinical trial. JAMA Psychiatry, 73, 955–962.
23.
SimonoffE.TaylorE.BairdG.BernardS.ChadwickO.LiangH.WhitwellS.RiemerK.SharmaK.SharmaS. P.WoodN.KellyJ.GolaszewskiA.KennedyJ.RodneyL.WestN.WalwynR.JichiF. (2013). Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry, 54, 527–535.
24.
SwansonJ. M.AglerD.FinebergE.WigalS.FlynnD.FinebergK.QuintanaY.TalebiH. (2000). University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies. In GreenhillL.OsmanB. (Eds.), Ritalin: Theory and practice (2nd ed., pp. 405–430). Mary Ann Liebert.
TsujiiN.UsamiM.NayaN.TsujiT.MishimaH.HorieJ.FujiwaraM.IidaJ. (2021). Efficacy and safety of medication for attention-deficit hyperactivity disorder in children and adolescents with Common Comorbidities: A systematic review. Neurology and Therapy, 10, 499–522.
27.
WeissM. D.ChildressA. C.DonnellyG. A. E. (2021). Efficacy and safety of PRC-063, extended-release multilayer methylphenidate in adults with ADHD including 6-Month open-label extension. Journal of Attention Disorders, 25, 1417–1428.
28.
WeissM. D.CutlerA. J.KollinsS. H.DonnellyG. A. E. (2021). Efficacy and safety of a long-acting multilayer-release methylphenidate formulation (PRC-063) in the treatment of adolescent attention-deficit/hyperactivity disorder: A randomized, double-blind clinical trial with a 6-Month open-label extension. Journal of Child and Adolescent Psychopharmacology, 31, 610–622.
29.
WeissM. D.SurmanC.KhullarA.HeE.CataldoM.DonnellyG. (2021). Effect of a multi-Layer, extended-release methylphenidate formulation (PRC-063) on sleep in adults with ADHD: A randomized, Double-Blind, Forced-Dose, placebo-controlled trial followed by a 6-month open-label extension. CNS Drugs, 35, 667–679.
30.
WeissM. D.SurmanC.KhullarA.OwensJ.HeE.CataldoM.DonnellyG. (2021). Effect of a multilayer, extended-release methylphenidate formulation (PRC-063) on sleep in adolescents with attention-Deficit/Hyperactivity Disorder: A randomized, double-blind, fixed-dose, placebo-controlled trial followed by a 6-month open-label follow-up. Journal of Child and Adolescent Psychopharmacology, 31, 623–630.
31.
WigalS. B.GuptaS.GuintaD.SwansonJ. M. (1998). Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bulletin, 34, 47–53.
32.
WigalS. B.WigalT.ChildressA.DonnellyG. A. E.ReizJ. L. (2020). The time course of effect of multilayer-release methylphenidate hydrochloride capsules: A randomized, double-blind study of adults with ADHD in a simulated adult workplace environment. Journal of Attention Disorders, 24, 373–383.
33.
WolraichM.BrownL.BrownR. T.DuPaulG.EarlsM.FeldmanH. M.GaniatsT. G.KaplanekB.MeyerB.PerrinJ.PierceK.ReiffM.SteinM. T.VisserS. (2011). ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128, 1007–1022.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
